MiNK Therapeutics Announces promising preclinical activity of MiNK-215 against colorectal cancer liver metastases at AACR
New York, April 08, 2024 - MiNK Therapeutics, a clinical-stage biopharmaceutical company, revealed promising preclinical data for its investigational iNKT cell therapy, MiNK-215, targeting colorectal cancer liver metastases. The announcement was made during the American Association for Cancer Research (AACR) Meeting held in San Diego, CA.
MiNK Therapeutics is focused on developing and commercializing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company’s latest research highlights their efforts to target fibroblast activation protein (FAP) using an IL-15 armored approach in CAR-iNKT cell therapy.
The study presented at the AACR Meeting showcased promising results in the treatment of colorectal cancer liver metastases using MiNK-215. While still in the preclinical stage, the therapy demonstrated significant anti-tumor activity.
Colorectal cancer is one of the most prevalent cancer types worldwide, with liver metastases being a common occurrence and often leading to poor patient outcomes. Current treatment options for colorectal cancer liver metastases are limited, and there is an unmet medical need for more effective therapies.
MiNK Therapeutics’ MiNK-215 therapy targets FAP, a protein highly expressed in tumor stroma and associated with an aggressive tumor microenvironment. Through its innovative armored IL-15 approach, the therapy enhances the activation and expansion of iNKT cells, which are known for their cytotoxic activity against cancer cells.
The presentation at the AACR Meeting provided preclinical data demonstrating the efficacy of MiNK-215 in reducing tumor burden and inhibiting cancer growth in an animal model of colorectal cancer liver metastases. These positive results indicate the potential of MiNK-215 as a promising therapeutic option for patients with metastatic colorectal cancer.
Further challenges lie ahead for MiNK Therapeutics as they work toward advancing MiNK-215 into clinical trials. The company aims to evaluate the therapy’s safety profile and efficacy in humans, with the ultimate goal of obtaining regulatory approval and bringing a novel treatment option to colorectal cancer patients.
In summary, MiNK Therapeutics’ MiNK-215 has shown promising preclinical activity against colorectal cancer liver metastases. By targeting FAP using an IL-15 armored approach, the therapy has demonstrated significant anti-tumor effects in animal models. Moving forward, clinical trials will be conducted to assess the therapy’s safety and efficacy in humans.
FAP-Targeting CAR-iNKT Cell Therapy Shows Promise Against Colorectal Cancer Liver Metastases in Preclinical Study at AACR
Comments